Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEI-PIP3
- Development stage
- Preclinical
- Lead developer
- Ben-Gurion University of the Negev
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
PEI-PIP3 is an experimental polymeric carrier-mediated complex consisting of branched polyethyleneimine (PEI, specifically 25 kDa PEI-25) and the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3). Developed by researchers at Ben-Gurion University of the Negev, it is designed as a "second messenger therapeutic" to overcome cellular insulin resistance. PIP3 is a key mediator of insulin signaling, but its high negative charge and membrane impermeability prevent direct cellular uptake. By complexing PIP3 with the cationic polymer PEI, the resulting nanoparticle formulation facilitates trans-membrane delivery. PEI-PIP3 bypasses proximal insulin signaling defects (upstream of endogenous PIP3 generation) to directly activate downstream effectors, stimulating Akt phosphorylation and GLUT4 translocation to restore glucose uptake in insulin-resistant muscle and adipose cells.
- Other names
- PEI-25/PIP3PEI/PIP3polyethyleneimine-phosphatidylinositol-3,4,5-trisphosphate complex
02
Targets
PDK (Pyruvate dehydrogenase kinase isoform 1)AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on PEI-PIP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEI-PIP3.